Our leaders talk about how Amneal has diversified beyond generics to deliver value in complex retail generics, biosimilars, injectables, specialty and international.
As of August 4, 2023, Amneal has 3 reportable business segments: 1) Generics (includes retail, injectables & biosimilars revenue), 2) Specialty and 3) AvKARE (includes distribution, government label & institutional revenue).
Our broad portfolio of approximately 270 generic and specialty pharmaceuticals is the foundation from which we make healthy possible. And we expanded our portfolios to institutions, in biosimilars and across select international markets.
We’re committed to delivering value. Learn more about the meaningful difference we’re making for people and healthcare.
Our culture is driven by actions that inspire us to Rise, Lead and Succeed – for patients and their families.
Apply your passion and talents to help us touch more lives.